View Older Stories View More Recent Stories

Nov 28, 2018 08:35AM Eisai and METAvivor Team Up to Launch Elements as the Latest #ThisIsMBC Initiative at the 2018 San Antonio Breast Cancer Symposium
Oct 24, 2018 10:00AM Eisai and Oklahoma Health Care Authority Enter Value-Based Agreement for FYCOMPA
Oct 17, 2018 07:30PM Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At The 11th Clinical Trials On Alzheimer's Disease (CTAD) Conference
Oct 16, 2018 08:08AM Eisai To Present New Research On Human Genetics And Drug Discovery At ASHG Conference 2018
Oct 4, 2018 07:30AM Eisai Announces New Data on the Effect of Anti-Obesity Agent BELVIQ® (lorcaserin HCl) on Prevention and Remission of Type 2 Diabetes Presented at the European Association for the Study of Diabetes (E
Sep 28, 2018 02:58PM Eisai Reports FDA Approval of FYCOMPA in Pediatric Patients as Young as 4 Years Old for the Treatment of Partial-Onset Seizures
Sep 28, 2018 02:54PM Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures
Aug 27, 2018 11:56AM Eisai Announces Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ® Presented at the European Society of Cardiology and Published in the New England Journal of Medicine
Aug 17, 2018 08:00AM Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Aug 16, 2018 04:11PM Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Jul 18, 2018 08:00AM Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At Alzheimer's Association International Conference 2018
Jul 17, 2018 09:00AM Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®
Jul 9, 2018 10:20PM Eisai Announces Acceptance of BAN2401 Phase II Results for Oral Presentation at the 2018 Alzheimer's Association International Conference (AAIC)
Jun 12, 2018 04:30PM Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts
Jun 11, 2018 02:00PM Lihua Yu, Ph.D., Appointed President & Chief Data Sciences Officer, H3 Biomedicine
Jun 5, 2018 01:58PM Eisai, Biogen (BIIB) Report Phase II Study Of Elenbecestat Demonstrated Safety And Tolerability In MCI And Mild To Moderate AD At 18-Months
Jun 5, 2018 01:55PM Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months
Jun 3, 2018 06:00PM Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types
May 24, 2018 07:34PM Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
Apr 9, 2018 10:00AM Morphotek Announces Agreement to License its Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical Co., Ltd. for Development of a Therapeutic Antibody-Drug Conjugate (ADC)*
Jan 24, 2018 10:00AM Morphotek To Present Poster On CA125 Suppression Of Humoral Immune Responses Of Antibodies At The Upcoming ASCO-SITC Clinical Immuno-oncology Symposium
Jan 10, 2018 09:00AM Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Jan 9, 2018 06:45AM Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Ca
Dec 11, 2017 10:00AM Morphotek And Rockefeller University Form A Sponsored Research Agreement To Study The Immunosuppressive Effects Of The Tumor Shed Antigen CA125 And Its Potential Impact In Future Patient Therapies
Dec 7, 2017 10:00AM Morphotek To Present Its Proprietary RESPECT™ Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego
Dec 4, 2017 10:00AM Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression
Nov 13, 2017 03:00PM Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon
Oct 3, 2017 08:00AM Eisai Inc. and Grupo Biotoscana Sign Exclusive Licensing Agreement for the Commercialization of Eisai's Oncology and Neurology Products throughout Latin America
Sep 19, 2017 10:00AM Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th Annual World ADC In San Diego
Sep 6, 2017 10:00AM Morphotek Announces Collaboration Agreement With The Johns Hopkins University To Research And Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
Sep 5, 2017 10:00AM Morphotek®, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®
Jul 26, 2017 06:40PM FDA Approves Eisai's FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures
Jul 11, 2017 10:00AM Morphotek Announces Publication Uncovering One Of The Mechanisms By Which The Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab
Apr 26, 2017 10:00AM Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The Upcoming 13th Annual PEGS Summit In Boston
Apr 3, 2017 09:00AM Morphotek Launches Antibody Drug Conjugate Services Business
Mar 28, 2017 10:00AM Morphotek to Present Three Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting 2017
Mar 23, 2017 08:06AM Eisai to Launch New Medikidz Epilepsy Comic Book at the National Walk for Epilepsy
Mar 22, 2017 10:00AM Morphotek And Sandy Rollman Ovarian Cancer Foundation Launch Educational Resource On Clinical Trials
Dec 19, 2016 01:32PM Eisai and Arena (ARNA) Announce BELVIQ Approval in Brazil
Dec 19, 2016 01:30PM Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil
Dec 12, 2016 07:01AM Merck (MRK) and Eisai Reports Encourating Phase 1b/2 KEYTRUDA/HALAVEN Combo Results
Dec 12, 2016 07:00AM Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA® (pembrolizumab) and Eisai's HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer P
Oct 26, 2016 02:27PM Eisai's LENVIMA® (lenvatinib) Nominated for Galien Foundation's Best Pharmaceutical Product
Oct 26, 2016 08:10AM Eisai Launches New Medikidz Epilepsy Comic Book in Conjunction with Lennox-Gastaut Syndrome (LGS) Awareness Day
Oct 3, 2016 09:00AM Morphotek and Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America
Oct 3, 2016 08:07AM Arena Pharma (ARNA), Eisai Announces Availability of New Once-Daily BELVIQ XR
Oct 3, 2016 08:06AM Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
Sep 22, 2016 02:00PM New #ThisIsMBC Campaign Seeks to Raise Awareness of Metastatic Breast Cancer by Encouraging People with This Rarely Discussed, Deadly Stage of the Disease to Share Their Experiences
Sep 21, 2016 02:00PM Myths and Truths About Thyroid Cancer Educational Initiative Honors Thyroid Cancer Awareness Month with Launch of New #TruthAboutTC Social Media Challenge
Sep 15, 2016 08:00AM Eisai Establishes AiM Institute to Discover Human Biology Driven Precision Medicines
View More Recent Stories View Older Stories